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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant condition, caused by mutations in either
the TSC1 or TSC2 gene. It has widespread systemic manifestations and is associated with significant neurological
morbidity. In addition to seizures and cerebral pathology including cortical tubers, subependymal nodules,
subependymal giant cell astrocytoma and abnormal white matter, there are recognised neuropsychiatric difficulties
including intellectual disability, autism spectrum disorder (ASD) and a range of learning and behaviour problems,
recently conceptualised as “tuberous sclerosis-associated neuropsychiatric disorders”, or “TAND”. ASD in TSC is of
particular importance because (1) it affects up to 50% of people with TSC and is a source of considerable difficulty
for them and their families and (2) it provides a model for considering neurobiological pathways involved in ASD.
Multiple factors are implicated in the development of ASD in TSC, including (1) seizures and related
electrophysiological factors, (2) cerebral pathology, (3) genotype and (4) child characteristics. However, the
neurobiological pathway remains unclear. We will conduct a systematic review to investigate and synthesise
existing evidence about the role of these risk factors, individually and in combination, in leading to the
development of ASD.
Methods: Our review will report on all studies that include one or more of four predefined risk factors in the
development of ASD in children with TSC. We will search five databases: MEDLINE, EMBASE, PubMed, The Cochrane
Library and Web of Science (Conference Proceedings Citation Index). Studies will be selected for reporting after two
authors independently (1) review all titles and abstracts, (2) read full text of all appropriate papers and (3) assess for
bias using the Newcastle-Ottawa Scale recommended by the Guidelines for Meta-Analysis and Systematic Reviews
of Observational Studies (MOOSE guidelines) and the ROBINS-I.
Discussion: To our knowledge, this is the first systematic review investigating multiple risk factors in the
development of ASD in children with TSC. Clarifying the evidence in this area will be important to researchers in
the field and to clinicians providing prognostic information to families.
Systematic review registration: PROSPERO CRD42016042841
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Background
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant condition caused by a mutation in either the TSC1
gene, located on chromosome 9q34.13, or the TSC2
gene, located on chromosome 16p13.3 [1, 2]. In 10–15%,
a mutation is not identified. The genes code for the
proteins hamartin (TSC1) and tuberin (TSC2) which
form a complex that regulates the mTOR cell signalling
pathway, responsible for important aspects of cell
growth and differentiation [3].
The clinical manifestations of TSC are highly variable.
A diagnosis of TSC is made in individuals who meet
internationally recognised diagnostic criteria. A definite
diagnosis is made when an individual has two or one
major with two or more minor clinical features. TSC
may also be diagnosed with genetic testing [4].
The major sources of morbidity in TSC are the neuro-
logical abnormalities. Epilepsy affects up to 93% of
people with TSC [5]. In the brain, cortical tubers, su-
bependymal nodules (SENs), subependymal giant cell
astrocytomas (SEGAs) and abnormal white matter are
associated with neurodevelopmental problems [6, 7].
Intellectual disability, ASD and other learning and
behaviour disorders cause considerable difficulties for
children and their families. These problems have re-
cently been conceptualised as “TSC-associated neuro-
psychiatric conditions” or “TAND” [8].
This review focuses on the relationship between TSC
and ASD. Whilst the association between TSC and ASD
has been recognised since 1979 [9], it is only since the
early 1990s that research in the field has tried to estab-
lish why this association exists. ASD is reported to affect
between 16 and 55% of children with TSC [10–12].
Understanding the development of ASD in TSC not only
is important for individuals affected by TSC but also
could provide valuable insights into the development of
idiopathic ASD.
The risk factor groups broadly implicated in the
neurobiological pathway to ASD are (1) seizures and re-
lated electrophysiological factors, (2) neurostructural
factors and (3) genotype. Although there has been less
of a focus in the literature, the authors also regard (four)
individual child characteristics (gender, perinatal history
and socio-economic status) and family history of neuro-
developmental problems to be of importance, as these
are considered to be central in the etiology of all devel-
opmental disorders in children.
Seizures are thought to be pivotal in the development
of ASD in TSC. Research has particularly implicated in-
fantile spasms and other seizures that occur at an early
age [13–15]. However, this is only part of the picture.
Other seizure types, age of seizure onset, seizure burden
and interictal EEG activity are all potential contributors.
Bombardieri has shown that early control of seizures
improves long-term outcomes in children with TSC,
demonstrating that children whose seizures were treated
within a week of onset did not develop ASD, compared
to a group with delayed treatment [16]. Cusmai had
similar findings, showing much lower, but not absent,
rates of ASD in children whose seizures were treated
early [14]. Although Bombardieri’s sample had the TSC2
genotype, neither of these studies accounted for any
other co-existent risk factors in analysis. Numis, in a
study of children and adults, has considered multiple
risk factors simultaneously and found not only that earl-
ier age of onset and more frequent seizures increased
ASD risk but also that ASD may be associated with per-
sistent EEG activity in particular brain regions [11].
Which of the seizure factors is of most significance and
how these factors interact to affect outcomes in children
is unclear.
There is evidence supporting the role of cortical tubers
[17–19], SEGAs [20] and white matter disorganisation
[21] in ASD development. In early work, Bolton found
that the number and temporal lobe location of tubers
were associated with ASD [17]. These findings have not
been consistently replicated. In contrast, Walz reported
tuber location to be of no significance to ASD outcome
[22]. Other works have looked at the impact of tuber
count on development generally, but not ASD specific-
ally [23, 24]. Furthermore, both Gallagher and Numis
have reported that different tuber “types” may impact
ASD severity [11, 19].
The presence of the TSC2 gene mutation may also
confer a worse overall developmental prognosis [19, 25].
Numis has reported that patients with TSC and ASD
had fewer TSC1 mutations [11]. By comparison, Kothare,
reporting on a large sample from a natural history data-
base of 919 patients, could not establish a relationship
between TSC2 and ASD, but his group acknowledged that
data was collected from multiple institutions, with no con-
sistent guidelines for reporting or diagnosing ASD [25].
Whilst there are several reviews of this topic, none has
been conducted in a systematic fashion to report on all
the published literature. Curatolo’s 2010 review consid-
ered pathogenic pathways leading to ASD in TSC, but
selected studies based on the novelty and author deter-
mined importance and relevance [26]. No reviews have
considered the relationship between all four major risk
factor groups. This interaction between the risk factors
is important, and a review that aims to clarify the con-
tributing role of each factor is needed. In addition, the
early life onset of TSC and the developmental problems
that arise also mean that a paediatric focus is required.
Our review has been methodically designed to report on
all paediatric studies that consider a set of predefined
risk factors, either separately or in combination, for the
development of ASD in TSC.
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The risk factors we will consider in our review are
as follows:
1. Seizures and related electrophysiological factors.
2. Neurostructural factors (tubers, SEGAs, SENs, white
matter abnormalities).
3. TSC genotype.
4. Child characteristics (gender, perinatal factors,
socio-economic status and family history of ASD).
A systematic review of the literature to explore what is
currently known about the role of risk factors, individu-
ally and in combination, is needed to determine future
research directions and provide information for better
clinical counselling and management.
We aim to answer the questions (1) what are the risk
factors for the development of ASD in children with
TSC and (2) how do those risk factors interact?
This review is registered on the PROSPERO database




Cohort studies that consider the impact of any of the
predefined risk factors on the development of ASD and
case-control studies that report on children with TSC
and ASD and investigate associated predefined risk
factors will be included.
Studies must specifically address the question of the
impact of at least one of the predefined risk factors on
the development of ASD in TSC in a paediatric popula-
tion. The mean age of subjects should be less than
18 years.
The participants for our review are considered to be
children (below 18 years of age) with TSC.
The exposure is one or more of the four predefined
risk factors for both cohort and case-control studies. For
the purposes of this review, the risk factor groups are
being considered in the following way:
1. Seizures and related electrophysiological factors: we
will report on studies that consider (1) seizure type
(and include infantile spasms as a separate subset),
(2) age at seizure onset and (3) seizure burden and/
or seizure severity. We will report on studies that
consider EEG abnormalities including (1)
epileptiform discharges and (2) slowing of
background activity.
2. Neurostructural factors: we will report on studies
that consider the role of (1) tuber number, (2) tuber
size, (3) tuber type and (4) total tuber volume. We
will report on studies that consider (1) white matter
bands or (2) abnormal white matter. We will report
on studies that consider SENs or SEGAs (1) number,
(2) size or (3) location.
3. Genotype: we will report on studies that consider
the role of a TSC1, TSC2 or “unknown TSC” gene
mutation.
4. Child characteristics: we will report on studies that
consider the role of perinatal factors, child gender,
family history of ASD and socio-economic factors in
the development of ASD in TSC.
In cohort studies, the comparator is an absence or
reduction in exposure to one of the predefined risk
factors. In case-control studies, the comparator is chil-
dren with TSC who do not have ASD.
The primary outcome measure is the incidence of
ASD in cohort studies and the presence of any of the
four predefined risk factors in case-control studies.
Our exclusion criteria are review papers (systematic or
narrative), randomised controlled trials, case reports of
less than five children, opinions, letters and editorials.
Relevant reviews will have reference lists hand checked.
Search strategy
Five databases will be searched: MEDLINE, EMBASE,
PubMed, The Cochrane Library and Web of Science
(Conference Proceedings Citation Index). The database
search strategies were developed with the assistance of a
senior tertiary hospital librarian with experience in sys-
tematic reviews. The strategy was developed to capture
all studies that would meet the above eligibility criteria.
In addition, the hand searching of review paper refer-
ences will provide further assurance that all eligible
papers have been located. The full search strategy is
included as an additional file (Additional file 1).
The search will not be limited to English. When non-
English papers are found, journals and authors will be
contacted to ask if an English version is available. When
an English version is not available, the abstracts will be
translated using the Google Translator tool to assess
potential eligibility of the paper. If a non-English paper
is to be included in the systematic review, we will source
translators from our international research networks.
The search will be limited to humans. We are not
intending to search for unpublished materials.
Study selection
The titles and abstracts of all studies generated through
the combined database searches will be merged using
reference management software and duplicates removed.
All titles and abstracts will be screened by two authors
independently. All studies that meet the eligibility cri-
teria on screening titles and abstracts will be sourced
and read in full. Where data are not available about
subject age, authors will be contacted to provide this, to
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determine if the study can be included. Disagreements
will be resolved through a third author.
A PRISMA study flow diagram will be presented.
Data extraction
A standardised, pre-piloted form will be used to extract
data from the included studies for assessment of quality
and evidence synthesis. Extracted information will in-
clude (1) number of participants; (2) source of partici-
pants (community sample, general hospital sample,
tertiary referral centre); (3) participant demographics
(age, gender); (4) how the diagnosis of TSC was con-
firmed (guidelines, clinical notes, other); (5) what ASD
diagnostic tools were used; (6) the number of partici-
pants with a diagnosis of ASD; (7) what risk factors were
assessed (electrophysiological factors, neuroanatomic
factors, genotype and child characteristics); (8) how the
risk factor exposure was measured; (9) co-occurrence of
intellectual disability; (10) reported outcomes, statistical
adjustments and statistical significance and (11) informa-
tion for assessment of risk of bias.
Of importance is the approach that study authors take
to the diagnosis of ASD. We intend to report on the
method used for diagnosis. We recognise that some
studies will diagnose subjects with ASD using a clearly
defined diagnostic process or a tool administered by an
appropriate person, with wide clinical acceptance. This
approach recognises that while multidisciplinary clinical
team assessment is the best practice for ASD diagnosis,
some tools have acceptable accuracy for diagnosis for
research. As such, some studies will determine the pres-
ence or absence of ASD using the best practice clinical
assessment and apply an appropriate classification sys-
tem at the time the study was done, with DSM criteria
(III/IV/V) or (ICD-9/10). In accordance with the current
DSM-V recommendations, studies that have classified
children as “autistic disorder”, “Asperger’s disorder” or
“pervasive developmental disorder not otherwise speci-
fied” will be given the diagnosis of autism spectrum dis-
order. Other studies may use the Autism Diagnostic
Observation Scale (any version) or Autism Diagnostic
Interview (original or revised) to make a diagnosis.
Risk of bias assessment
Risk of bias will be assessed using two tools. We will
follow the Guidelines for Meta-Analysis and Systematic
Reviews of Observational Studies (MOOSE guidelines)
[27], using the Newcastle-Ottawa scale for case-control
studies [28] and ROBINS-I for cohort studies [29].
Data analysis and synthesis
We will enter data into a series of 2 × 2 tables showing
ASD or no ASD and exposure to defined risk factor or
no exposure to defined risk factor. We will record all
relative risk or odds ratios where provided, and will
otherwise use the 2 × 2 tables to calculate these values.
Confidence intervals, p values and any statistical adjust-
ments will be recorded. The decision to report relative
risk (RR) or odds ratio (OR) values will be made on the
basis of which has been reported in the majority of stud-
ies included in that subgroup analysis. We will convert
values to the appropriate form for studies using the
alternative method.
Data synthesis will be considered separately for each
of the four risk factor groups, with an additional section
given to discussing any papers that considered the inter-
actions of any of the predefined risk factors. We do not
intend to use individual subject data from studies. When
pooling results for single-factor studies, we expect that a
crude OR will be reported and we will also include crude
ORs from multifactor studies into crude OR meta-
analyses if this data is available for single factors. We will
also conduct meta-analyses of adjusted ORs if more than
one study reports adjusted ORs for one or more factors.
When adjustments are made for analyses that include
single or multiple risk factors, we will extract the factors
adjusted for in the analysis and present this information
and consider whether it is likely to have influenced
reported results. We will pool only studies in which the
exposure of interest was measured using similar
methods across the pooled studies.
Aggregate subject data will be used and a narrative
synthesis presenting quantitative estimates of increased
likelihood of a diagnosis of ASD given different risk
factors will be done. We plan to present the findings as
a series of forest plots for the different risk factors being
considered. If the included studies are sufficiently
homogenous, a meta-analysis will be considered using a
random effects model.
We will consider subgroup analyses to identify import-
ant differences in groups when considering (1) source of
participants (community sample, general hospital sam-
ple, tertiary referral centre), (2) participant demographics
(age, gender), (3) how the diagnosis of TSC was
confirmed (guidelines, clinical notes, other), (4) what
ASD diagnostic tools were used, (5) how the risk factor
exposure was measured, (6) co-occurrence of intellectual
disability and (7) overall risk of bias.
We will assess heterogeneity by visually inspecting
forest plots and calculating I2 statistic before pooling
data. If there is high heterogeneity, we will assess
whether clinical or methodological factors have contrib-
uted to this, and if there are clinical features that have
led to the heterogeneity, we will perform and present
subgroup analyses, so the cause and magnitude of differ-
ences created by clinical variation are clear.
To assess the potential impact of methodological
differences, we will perform sensitivity analyses, when
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sufficient studies using different methods are available,
and report the effect of the inclusion and exclusion of
different methods.
We will assess for publication bias. Whilst there are
no specific guidelines for assessing this in systematic
reviews of cohort studies, our approach will be to con-
sider adjusted and unadjusted risk factor effects se-
parately and observe any asymmetry in results. These
results will then determine the appropriateness of
further statistical testing.
Overall quality of evidence (GRADE system)
We plan to give an overall assessment of the quality of
the body of evidence using the GRADE approach [30].
The methodology for this review was developed using
the PRISMA-P checklist (Additional file 2).
Discussion
The review aims to report on the likelihood of the devel-
opment of ASD in a child with TSC exposed to one or
more of the risk factors being studied. Firstly, this
provides valuable prognostic information for families
and allows clinicians to flag children likely to need refer-
ral to early intervention services. Secondly, it assists in
identifying pathways that contribute to ASD develop-
ment, providing opportunities to target medical inter-
ventions. Finally, clarifying what the literature currently
states about the role of clinical risk factors in the devel-
opment of ASD in TSC is important for streamlining
and directing future research efforts.
Amendments to the protocol
The protocol published with PROSPERO had undergone
one amendment prior to the submission of this manu-
script for publication. The amendment was to include
Web of Science (Conference Proceedings Citation Index)
in the database search. Any future amendments to the
protocol will also be registered with PROSPERO and
available online.
Dissemination
Our intention is to submit the review to a major inter-
national journal in the field for publication.
Additional files
Additional file 1: The full search strategy. (PDF 636 kb)
Additional file 2: PRISMA-P checklist. (DOC 85 kb)
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